open access
Vol 62, No 6 (2012)
Review paper
Published online: 2012-12-28
Get Citation
Diagnostics and treatment options in Triple-Negative Breast Cancer
,
Nowotwory. Journal of Oncology 2012;62(6):450-454.
open access
Vol 62, No 6 (2012)
Review article
Published online: 2012-12-28
Abstract
Triple-negative breast cancer (TNBC) refers to about 15–20% of all breast cancer cases. It is characterised by the
worst clinical outcome and poor prognosis. TNBC is defined by the lack of expression of estrogen, progesterone
and HER-2 receptors. Hormone receptor assays and HER2 testing is taken by immunohistochemistry examination
or fluorescence in-situ hybridization (FISH). Surgery remains the most frequently used mode of primary therapy
and breast conservation have the same outcomes as mastectomy. Patients with TNBC do not benefit from available
receptor-targeted therapy. Due to an absence of defined clinical targets, conventional chemotherapy remains the
standard treatment. Despite its worse clinical outcome TNBC when compared with other breast cancer subtypes
often exhibits superior sensitivity to chemotherapy. Many targeted therapeutic agents show promise in early stage
studies, but their clinical performance has yet to be definitively proven.
worst clinical outcome and poor prognosis. TNBC is defined by the lack of expression of estrogen, progesterone
and HER-2 receptors. Hormone receptor assays and HER2 testing is taken by immunohistochemistry examination
or fluorescence in-situ hybridization (FISH). Surgery remains the most frequently used mode of primary therapy
and breast conservation have the same outcomes as mastectomy. Patients with TNBC do not benefit from available
receptor-targeted therapy. Due to an absence of defined clinical targets, conventional chemotherapy remains the
standard treatment. Despite its worse clinical outcome TNBC when compared with other breast cancer subtypes
often exhibits superior sensitivity to chemotherapy. Many targeted therapeutic agents show promise in early stage
studies, but their clinical performance has yet to be definitively proven.
Abstract
Triple-negative breast cancer (TNBC) refers to about 15–20% of all breast cancer cases. It is characterised by the
worst clinical outcome and poor prognosis. TNBC is defined by the lack of expression of estrogen, progesterone
and HER-2 receptors. Hormone receptor assays and HER2 testing is taken by immunohistochemistry examination
or fluorescence in-situ hybridization (FISH). Surgery remains the most frequently used mode of primary therapy
and breast conservation have the same outcomes as mastectomy. Patients with TNBC do not benefit from available
receptor-targeted therapy. Due to an absence of defined clinical targets, conventional chemotherapy remains the
standard treatment. Despite its worse clinical outcome TNBC when compared with other breast cancer subtypes
often exhibits superior sensitivity to chemotherapy. Many targeted therapeutic agents show promise in early stage
studies, but their clinical performance has yet to be definitively proven.
worst clinical outcome and poor prognosis. TNBC is defined by the lack of expression of estrogen, progesterone
and HER-2 receptors. Hormone receptor assays and HER2 testing is taken by immunohistochemistry examination
or fluorescence in-situ hybridization (FISH). Surgery remains the most frequently used mode of primary therapy
and breast conservation have the same outcomes as mastectomy. Patients with TNBC do not benefit from available
receptor-targeted therapy. Due to an absence of defined clinical targets, conventional chemotherapy remains the
standard treatment. Despite its worse clinical outcome TNBC when compared with other breast cancer subtypes
often exhibits superior sensitivity to chemotherapy. Many targeted therapeutic agents show promise in early stage
studies, but their clinical performance has yet to be definitively proven.
Get Citation
About this articleTitle
Diagnostics and treatment options in Triple-Negative Breast Cancer
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
450-454
Published online
2012-12-28
Page views
4054
Article views/downloads
39820
Bibliographic record
Nowotwory. Journal of Oncology 2012;62(6):450-454.
Authors
Monika Ryś-Bednarska
Hanna Romanowicz